Astellas Pharma and Potenza Therapeutics entered into an exclusive research and development collaboration in April 2015 with the goal of advancing a portfolio of novel antibodies for immuno-oncology therapy. Since entering into the partnership, the companies have worked together closely with Potenza leading drug discovery while Astellas leads clinical development to advance several programs with novel mechanisms of action targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells.